Important breakthroughs in medical treatments have improved outcomes for patients
suffering from several types of cancer. However, many oncological treatments approved by …

Introduction: There are growing concerns among European health authorities regarding
increasing prices for new cancer medicines, prices not necessarily linked to health gain and …

The burden of cancer from a clinical, societal, and economic viewpoint continues to increase
in all parts of the world, along with much debate regarding how to confront this. Projected …

Despite presence of substantial evidence suggesting the pivotal role of amyloid (Aβ) in
Alzheimer's disease (AD), very few therapeutic agents have been able to ameliorate the …

The increasing number and high prices of orphan drugs have triggered concern among
patients, payers, and policymakers about the affordability of new drugs approved using the …

Capitalizing a Cure takes readers into the struggle over a medical breakthrough to
investigate the power of finance over business, biomedicine, and public health. When …

Chimeric antigen receptor (CAR) T-cell (CAR-T) therapies genetically modify a person's own
T cells to bind to antigens expressed on cancer cells. 1, 2 CAR-T has generated sizable …

Despite implementing hundreds of strategies, cancer drug development suffers from a 95%
failure rate over 30 years, with only 30% of approved cancer drugs extending patient …

Background Most cancer drugs enter the US market first. US Food and Drug Administration
(FDA) approvals of new cancer drugs may influence regulatory decisions in other settings …

Importance Oral chemotherapy is often dispensed to patients as a 1-month supply, with pill
dose and package size predetermined by the drug manufacturer; thus, changing the patient …